Skip to main content

Table 3 Summary of results from studies of first-line therapy with octreotide LAR in patients with acromegaly

From: Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas

Reference

No of pts

Duration of treatment

Patients meeting criterion for GH control (%)

Patients with IGF-1 normalization (%)

Mean tumor shrinkage (%)

% of patients with significant tumor shrinkage (definition of significant)

Colao et al 2001 [101]

15

12-24 months

73

53

53

80 (>20%)

Amato et al 2002 [99]

8

24 months

50

50

34.8

100 (>10%)

Ayuk et al 2004 [100]

25

48 weeks

62

64

NR

NR

Jallad et al 2005 [105]

28

6-24 months

NR

43

NR

76 (>25%)

Colao et al 2006 [102]

34

6 months

61

45.5

54 (median)

74 (>30%)

Cozzi et al 2006 [104]

67

6-108 months

69

70

62

82 (>25%)

Mercado et al 2007 [106]

68

48 weeks

44

34

39

75 (>20%)

Colao et al 2007 [103]

56

24 months

86

84

68

NR

Colao et al 2008 [127]

67

12 months

52

58

49

85 (>25%)

Colao et al 2008 [128]

40

48 weeks

NR

NR

35

73 (>20%)

  1. NR = not reported